Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment

Completed

Conditions studied: Non-small Cell Lung Cancer, Lung Cancer, Metastatic Cancer, Brain and Central Nervous System Cancer

In brief

This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.

Key facts

Study ID

NCT06557967

Run by

Daiichi Sankyo

People needed

22517

Starts

2024-03-01

Expected to finish

2024-09-30

Last updated by the study team

2024-12-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC
• Age 18+ years at the time of diagnosis of mNSCLC
• Additional inclusion criteria for 1st Line of Therapy cohort:
• Treated with systemic anti-cancer therapy in 1L setting
• Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts:
• Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting

You may not qualify if…

• Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period
• Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period

Where it is running

• ConcertAI Database — Cambridge, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.